FY2026 · ended Mar 31, 2026 · Revenue $1.09B, -4.3% YoY · Filed May 14, 2026
Prestige Consumer Healthcare Inc. (PBH) files with the SEC under industry code 2834, Pharmaceutical Preparations. In fiscal 2026, which ended Mar 31, 2026, it reported revenue of $1.1 billion and net income of $190.3 million. Free cash flow was $246.4 million. As of Jun 30, 2026 it held $89.1 million in cash and investments and $2.1 billion in total debt.
Revenue (TTM)
$1.10B
-1.4% vs year-ago TTM
Net income (TTM)
$172.01M
-19.2% vs year-ago TTM
Operating cash flow (TTM)
$249.40M
-9.6% vs year-ago TTM
Free cash flow (TTM)
$235.36M
-12.1% vs year-ago TTM
EPS (TTM)
$3.57
-16.2% vs year-ago TTM
Dividend per share
None
Shares outstanding
47.37M
-4.1% vs prior year
Net cash
$-1.97B
as of Jun 30, 2026
Operating margin
26.3%
FY 2027
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- PBH (NYSE)
- Fiscal year ends
- March 31
- Headquarters
- Tarrytown, NY
- SEC filer status
- Large accelerated filer
- SEC CIK
- 1295947
- Former names
- Prestige Brands Holdings, Inc. (until Aug 10, 2018)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Key figures
Fiscal-year totals from the annual reports. Balance sheet lines are as of each year end.
| Line | FY 2026 Mar 31, 2026 |
FY 2025 Mar 31, 2025 |
FY 2024 Mar 31, 2024 |
FY 2023 Mar 31, 2023 |
FY 2022 Mar 31, 2022 |
|---|---|---|---|---|---|
| Revenue | $1.1B | $1.1B | $1.1B | $1.1B | $1.1B |
| Operating income | $309.4M | $336.8M | $342.4M | -$22.4M | $329.9M |
| Net income | $190.3M | $214.6M | $209.3M | -$82.3M | $205.4M |
| Diluted EPS | $3.91 | $4.29 | $4.17 | -$1.65 | $4.04 |
| Operating cash flow | $257.6M | $251.5M | $248.9M | $229.7M | $259.9M |
| Free cash flow | $246.4M | $243.3M | $239.4M | $221.9M | $250.3M |
| Total assets | $3.5B | $3.4B | $3.3B | $3.4B | $3.7B |
| Total liabilities | $1.6B | $1.6B | $1.7B | $1.9B | $2.1B |
| Stockholders' equity | $1.9B | $1.8B | $1.7B | $1.4B | $1.6B |
| Cash and investments | $63.9M | $97.9M | $46.5M | $58.5M | $27.2M |
| Total debt | $1.0B | $1.0B | $1.1B | $1.4B | $1.5B |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Officer or director change
|
Aug 14, 2026 | Aug 10, 2026 |
| 10-Q | Quarterly report | Aug 6, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Results of operations, Regulation FD disclosure
|
Aug 6, 2026 | Aug 6, 2026 |
| 8-K |
Current report
Material agreement, New debt
|
Jul 15, 2026 | Jul 15, 2026 |
| 8-K/A | Amended current report | Jul 9, 2026 | Jun 12, 2026 |
| 8-K |
Current report
Material agreement, New debt, Regulation FD disclosure
|
Jul 6, 2026 | Jun 30, 2026 |
All 1000 Prestige Consumer Healthcare Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.